Podium to Practice: EHA 2025 – Multiple Myeloma: PREDATOR-MRD RANDOMIZED TRIAL
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Studies / Trials Discussed
S204 – DARATUMUMAB OR OBSERVATION FOR MINIMAL RESIDUAL DISEASE REAPPERANCE IN MULTIPLE MYELOMA: RESULTS FROM THE PREDATOR-MRD RANDOMIZED TRIAL
Studies/trials discussed:
S204 – DARATUMUMAB OR OBSERVATION FOR MINIMAL RESIDUAL DISEASE REAPPERANCE IN MULTIPLE MYELOMA: RESULTS FROM THE PREDATOR-MRD RANDOMIZED TRIAL
199 Bay Street #4000
Toronto, ON M5L 1A9
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.